Zafgen Appoints Patrick Loustau as President | Previous Release
Zafgen Appoints Patrick Loustau as President (NASDAQ:ZFGN)
Zafgen Appoints Patrick Loustau as President
Mr. Loustau Brings Over 20 Years of US and Global Management Experience
CAMBRIDGE, Mass., July 1, 2014 (GLOBE NEWSWIRE) -- Zafgen, Inc.
(Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity, today announced the appointment of Patrick Loustau
to the position of President.
has broad experience in creating and implementing differentiated global and market strategies, from clinical development through life cycle management and business development.
Most recently, he was the Senior Vice President for Global Commercialization (Cardiovascular & Metabolics) at Bristol-Myers Squibb, where he built a strong diabetes presence, growing sales from $158M to $1.6B in three years through both organic and external growth strategies that ultimately led to the $7B acquisition of Amylin.
"The addition of Patrick to our management team comes at a very exciting time for Zafgen," said Thomas Hughes, Ph.D., Chief Executive Officer, Zafgen, Inc.
is a seasoned professional, having shaped commercial strategy for major metabolic disease products in the U.S. and global markets.
business experience will prove especially valuable as we further develop Zafgen's
corporate strategy and solidify our position as an emerging leader in the development of therapeutics for difficult-to-treat metabolic diseases."
was previously with Novo Nordisk, where he
held the most recent role of Senior Vice President for Global Marketing & Medical Affairs (based in Copenhagen).
While at Novo Nordisk, he
rebuilt its global marketing and medical affairs team, implemented a globally aligned go-to-market model and increased diabetes sales in the U.S. by 76% in two years.
Mr. Loustau began his career with Parke-Davis in Paris, France, as a Human Resources and Training Manager.
attended the General Manager Program through Harvard Business School's
Executive Education track.
represents a unique value proposition in the biotech field and has the potential to dramatically impact patients and their families, ultimately transforming the way obesity and related metabolic diseases are treated," said Mr. Loustau